Early Residual Disease and Recurrence Monitoring of Early-Stage CRC

Abstract

Get full access to this article

View all access options for this article.

References

www.cancer.org/cancer/colon-rectal-cancer/about/key-statistics.html Accessed online Feb 5, 2021.

Chakrabarti

, Peterson

, Sriram

, Amit Mahipal

et al., Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions. World J Gastro Oncol. 2020 Aug 15; 12(8): 808–832.

American Cancer Society: Colorectal Cancer Facts & Figured 2020-2022. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf. Accessed online Feb 5, 2021.

Reinert

, Henriksen

, Christensen

et al., Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncology. 2019; 5 (8): 1125–1131.

Tie

, Wang

, Tomasetti

, Li

, Springer

et al., Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine. 2016; 8 (346): 346ra92.

Tie

, Cohen

, Wang

et al., Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. JAMA Oncology. 2019; 5(12): 1710-1717.

Peng

, Li

, Mo

, Ma

, Hu

, Zhang

et al., Prognostic value of circulating tumor DNA (ctDNA) detection during adjuvant chemotherapy in patients with stage III colorectal cancer: The interim report of a prospective, observational study. Journal of Clinical Oncology. 2020; 38, no.4_suppl.

Tarazona

, Gimeno-Valiente

, Gambardella

et al., Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Annals of Oncology. 2019; 30 (11): 1804–1812.

Parikh

, Van Seventer

, Marie Boland

, Hartwig

, Jaimovich

, Raymond

et al., A plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) assay to inform recurrence risk in colorectal cancer (CRC). Journal of Clinical Oncology. May 2019:3602–3602.

10.

Shinkins

, Nicholson

, Primrose

et al., The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: Results from the FACS trial. PLoS One. 2017; 12(3): e0171810.

11.

Young

, Womeldorph

, Johnson

. Early Detection of Colorectal Cancer Recurrence in Patients Undergoing Surgery with Curative Intent: Current Status and Challenges. Journal of Cancer. 2014; 5(4): 262–271.

12.

Parikh

, Van Seventer

, Siravegna

, Hartwig

et al., Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients. Under Review. Data on file.